2 completed, 1 not yet recruiting, 1 unknown. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Chemoembolization, Therapeutic: new trials by email Literature Review of Chemoembolization, Therapeutic trials Research Report on Chemoembolization, Therapeutic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tislelizumab Plus Chemotherapy and BACE for Unresectable NSCLC Tislelizumab, Intravenous Chemotherapy, Bronchial Artery Chemoembolization (BACE) - Unresectable Stage III Non-small Cell Lung Cancer, Tislelizumab | Phase 2 | Not yet recruiting | Sichuan Cancer Hospital and Research Institute | 39 | 2026-05-01 | 2026-05-01 |
| Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan Patient records - Hepatocellular Carcinoma Non-resectable, Chemoembolization, Therapeutic | Unknown | National Taiwan University Hospital | 500 | 2017-09-13 | 2017-09-15 | |
| Contrast-enhanced Ultrasound Evaluation of Chemoembolization Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound) - Hepatocellular Carcinoma, Chemoembolization, Therapeutic | Phase 3 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 131 | 2016-04-01 | 2025-05-06 |
| TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma TACE, RFA - Hepatocellular Carcinoma, Chemoembolization, Therapeutic | Phase 3 | Completed | Ming Zhao | 241 | 2015-05-01 | 2026-03-31 |
Adenocarcinoma (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Liver Diseases (2) · Liver Neoplasms (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2)
Medical Records (1) · perflutren (1) · tislelizumab (1)
Ming Zhao (1) · National Taiwan University Hospital (1) · Sichuan Cancer Hospital and Research Institute (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
China (2) · Taiwan (1) · United States (1)
Chien-Hung Chen, MD (1) · Guohui Xu, MD (1) · John Eisenbrey, PhD (1) · Ming Zhao, doctor (1) · Xuegang Yang, MD (1)
R01CA194307 (1)